- ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.
DaVita's (DVA) stock rating was reduced to 'neutral' from 'buy' at BofA/Merrill on Tuesday.
Here are Tuesday's top research calls, including an upgrade for Gilead Sciences, downgrades for Biogen and VF Corp., and new coverage for CBS.
The Centers for Medicare and Medicaid Services issued a request for information seeking comment from DaVita (DVA) on concerns of patient steering.